A Phase III Clinical Trial Evaluating DCVax-Brain Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to determine whether DCVax-L can slow the growth and recurrence of brain tumors and whether DCVax-L can extend overall survival.
Description
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
Details
| Condition | Glioblastoma |
|---|---|
| Age | 18years - 70years |
| Clinical Study Identifier | TX2331 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.